Enhancing on-target efficacy

Enabling oral administration

Improving tolerability

At PureTech, our R&D approach is centered on enhancing on-target efficacy, enabling oral administration or improving tolerability to unlock new classes of medicine that have been held back by one of these issues.

Unlocking the potential of validated efficacy

Across our pipeline, there are examples of how we start with a patient need and identify an approach that has proof of human efficacy, but key limitations have hindered the class from reaching its full potential. Examples include off-target effects, low bioavailability or poor tolerability.

Karuna’s KarXT

KarXT, which was invented at PureTech, has demonstrated notable improvements across schizophrenia symptoms – without the debilitating side effects of existing drugs – and is now poised to be the first new class of medicine in over 50 years for patients living with schizophrenia.


Allopregnanolone has proven efficacy but is only available as a 60-hour IV infusion. With LYT-300, we have achieved oral bioavailability approximately nine-fold greater than that of orally administered allopregnanolone, which significantly expands the potential of this validated mechanism.


Pirfenidone’s tolerability profile impacts patient adherence to an otherwise efficacious treatment, resulting in dose adjustments, discontinuations and ultimately poor patient outcomes. LYT-100 is designed to retain the potent and clinically-validated anti-fibrotic and anti-inflammatory activity of pirfenidone, and it has demonstrated favorable tolerability in multiple clinical studies.

Our publications